Trial halted early in search for better breast cancer control
NCT ID NCT03289039
Summary
This study tested whether adding a hormone-blocking drug (fulvestrant) to a targeted cancer drug (neratinib) worked better than the targeted drug alone for advanced breast cancer that had spread. It involved 21 women with specific types of breast cancer (HER2-positive and ER-positive) that had returned or spread despite previous treatments. The trial was terminated early, and its main goal was to see how long the treatment could keep the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Eastern Maine Medical Center
Brewer, Maine, 04412, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.